Mechanistically, high expression of BCAT1 reduces the NAD+/NADH ratio, increases mTORC1 activity, and promotes oxidative phosphorylation and nucleotide biosynthesis.64 The results of Zhang et al. illustrate the feasibility of targeting BCAAs metabolism in GBM for tumor therapy (Fig. 4). This evidence concerns the gene BCAT1 and glioblastoma.